Detecting cancer DNA in patients with severe blood disease
Official title: Liquid Biopsy for the Identification of Malignancy Associated Haemophagocytic Lymphohistiocytosis (HLH)
Run by Nottingham University Hospitals NHS Trust · NCT05702502 · Data updated 2026-11-12
This study is testing if a blood test for cancer DNA can help doctors find lymphoma earlier in patients with a severe blood disease called HLH.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 12 (estimated) |
| Sponsor | Nottingham University Hospitals NHS Trust Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Nottingham, Nottinghamshire) |
| Status | Recruiting |
| Started | June 30, 2023 |
| Main results expected | January 1, 2026 |
| Study ends | January 1, 2026 |
| Registry record updated | April 8, 2025 |
| Trial ID | NCT05702502 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 and older who have clinically confirmed HLH and have not received systemic anti-cancer therapy for more than 72 hours.
✕Probably not a fit
Patients whose HLH is already known to be caused by a non-malignant condition will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to identify circulating tumor DNA (ctDNA) in patients diagnosed with Haemophagocytic Lymphohistiocytosis (HLH), a severe condition often associated with lymphoma. By analyzing blood samples from patients with HLH, the study seeks to determine if ctDNA can be used as a biomarker for earlier diagnosis of lymphoma. The research highlights the challenges in diagnosing lymphoma in HLH patients due to overlapping symptoms with severe sepsis, which can lead to delayed treatment and poor outcomes. The goal is to improve survival rates by facilitating quicker and more accurate diagnosis of underlying lymphomas.
Why it matters
Potential benefit: If successful, this study could lead to earlier diagnosis and treatment of lymphoma in patients with HLH, potentially improving survival rates.
How similar studies have gone: While the use of ctDNA in lymphoma diagnosis is being explored, this specific approach in the context of HLH is novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion criteria: * Informed consent. * Age ≥18 years. * Clinically confirmed HLH. * High dose steroids and/or systemic anti-cancer therapy (SACT) for \<72 hours for the current episode of HLH (anakinra is not considered SACT). Prior steroid use \>14 days at the time of consent is permitted. * Patients with recurrent HLH may be included. * Patients already known to have underlying lymphoma, or have relapsed lymphoma may be included. Exclusion criteria: • Cause of HLH already known to be due to a non-malignant cause.
Where it's running
-
Nottingham Univeristy Hospitals NHS Trust
Nottingham, Nottinghamshire, United Kingdom Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
LB-208: a new oral treatment for adults with advanced solid tumors or lymphoma
This early study tests whether LB-208, taken once daily by mouth, is safe for adults with advanced solid tumors or lymphoma who have exhausted standard treatments.
-
Tailored exercise program to improve quality of life for adults with hematologic cancers
This pilot trial tests a personalized 16-week exercise program to see if it’s feasible and helpful for adults with acute myeloid leukemia, lymphoma, or multiple myeloma after first-line treatment.
-
CD19/CD22 CAR-T consolidation after second-line therapy for high-risk aggressive B-cell lymphoma
This trial tests whether CD19/CD22 CAR-T cell therapy given after a second-line response can help people with high-risk aggressive B-cell lymphoma stay in remission.
-
Low-dose Liposomal Amphotericin B for preventing fungal infections in adults with blood cancers and prolonged neutropenia
This study tests whether giving a daily 50 mg dose of liposomal amphotericin B can help prevent invasive fungal infections in adults with blood cancers who have prolonged low white blood cell counts.
-
Genetics of Blood Cancers in the U.S. population
This study tests how genetic factors relate to blood cancers by collecting saliva DNA and online health surveys from at least 10,000 U.S. adults.
-
Glofit-GemOx Bridging to Liso-cel for Relapsed/Refractory Large B-Cell Lymphoma
This trial tests whether a bridging therapy with Glofit-GemOx followed by lisocabtagene maraleucel helps people with relapsed or refractory large B-cell lymphoma.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.